Literature DB >> 29502635

Ten Years of Human Papillomavirus Vaccination in the United States.

Lauri E Markowitz1, Julianne Gee2, Harrell Chesson3, Shannon Stokley4.   

Abstract

Since human papillomavirus (HPV) vaccine was first introduced for females in the United States in 2006, vaccination policy has evolved as additional HPV vaccines were licensed and new data became available. The United States adopted a gender neutral routine HPV immunization policy in 2011, the first country to do so. Vaccination coverage is increasing, although it remains lower than for other vaccines recommended for adolescents. There are various reasons for low coverage, and efforts are ongoing to increase vaccine uptake. The safety profile of HPV vaccine has been well established from 10 years of postlicensure monitoring. Despite low coverage, the early effects of the HPV vaccination program have exceeded expectations. Published by Elsevier Inc.

Entities:  

Keywords:  human papillomavirus; human papillomavirus vaccine; immunization program

Mesh:

Substances:

Year:  2018        PMID: 29502635     DOI: 10.1016/j.acap.2017.09.014

Source DB:  PubMed          Journal:  Acad Pediatr        ISSN: 1876-2859            Impact factor:   3.107


  40 in total

1.  A Qualitative Analysis of Young Sexual Minority Men's Perspectives on Human Papillomavirus Vaccination.

Authors:  Mary A Gerend; Krystal Madkins; Shariell Crosby; Aaron K Korpak; Gregory L Phillips; Michael Bass; Magda Houlberg; Brian Mustanski
Journal:  LGBT Health       Date:  2019-09-26       Impact factor: 4.151

Review 2.  Addressing HPV vaccine myths: practical information for healthcare providers.

Authors:  Robert A Bednarczyk
Journal:  Hum Vaccin Immunother       Date:  2019-02-20       Impact factor: 3.452

3.  Excess Cancer Cases and Medical Costs Due to Suboptimal Human Papillomavirus Vaccination Coverage in California.

Authors:  Eleonore B Baughan; Erin M Keizur; Christopher A Damico; Elizabeth Mayfield Arnold; Jamie S Ko; Jeffrey D Klausner
Journal:  Sex Transm Dis       Date:  2019-08       Impact factor: 2.830

4.  Safety of the 9-Valent Human Papillomavirus Vaccine.

Authors:  Tom T Shimabukuro; John R Su; Paige L Marquez; Adamma Mba-Jonas; Jorge E Arana; Maria V Cano
Journal:  Pediatrics       Date:  2019-11-18       Impact factor: 7.124

5.  Immunogenicity and safety of a mixed vaccination schedule with one dose of nonavalent and one dose of bivalent HPV vaccine versus two doses of nonavalent vaccine - A randomized clinical trial.

Authors:  Vladimir Gilca; Chantal Sauvageau; Gitika Panicker; Gaston De Serres; Manale Ouakki; Elizabeth R Unger
Journal:  Vaccine       Date:  2018-10-09       Impact factor: 3.641

6.  Effect of State Immunization Information System Centralized Reminder and Recall on HPV Vaccination Rates.

Authors:  Peter Szilagyi; Christina Albertin; Dennis Gurfinkel; Brenda Beaty; Xinkai Zhou; Sitaram Vangala; John Rice; Jonathan D Campbell; Melanie D Whittington; Rebecca Valderrama; Abigail Breck; Heather Roth; Megan Meldrum; Chi-Hong Tseng; Cynthia Rand; Sharon G Humiston; Stanley Schaffer; Allison Kempe
Journal:  Pediatrics       Date:  2020-04-06       Impact factor: 7.124

7.  Improving Human Papillomavirus Vaccination in the United States: Executive Summary.

Authors:  Shannon Stokley; Peter G Szilagyi
Journal:  Acad Pediatr       Date:  2018-03       Impact factor: 3.107

8.  Using Inside Knowledge Campaign Materials to Improve Gynecologic Cancer Knowledge in Underserved Women.

Authors:  Mary Puckett; Julie Townsend; Jenny Rees Patterson; Donna Shaw; Yvonne Wasilewski; Sherri L Stewart
Journal:  J Womens Health (Larchmt)       Date:  2019-08-02       Impact factor: 2.681

9.  Missed opportunities for human papillomavirus vaccination at office visits during which influenza vaccine was administered: An AAP pediatric research in office settings (PROS) national primary care research network study.

Authors:  Mary Kate Kelly; Robert W Grundmeier; Alisa J Stephens-Shields; Russell Localio; Laura P Shone; Margaret Wright; Jennifer Steffes; Sharon G Humiston; Cynthia Rand; Christina Albertin; Abigail Breck; Dianna E Abney; Greta McFarland; Peter G Szilagyi; Alexander G Fiks
Journal:  Vaccine       Date:  2020-06-12       Impact factor: 3.641

10.  Effectiveness of 1, 2, and 3 Doses of Human Papillomavirus Vaccine Against High-Grade Cervical Lesions Positive for Human Papillomavirus 16 or 18.

Authors:  Michelle L Johnson Jones; Julia Warner Gargano; Melissa Powell; Ina U Park; Linda M Niccolai; Nancy M Bennett; Marie R Griffin; Troy Querec; Elizabeth R Unger; Lauri E Markowitz
Journal:  Am J Epidemiol       Date:  2020-04-02       Impact factor: 4.897

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.